Plasma Levels of Soluble AβPPβ as a Biomarker for Alzheimer's Disease with Dementia.
J Alzheimers Dis. 2019 Mar 18. doi: 10.3233/JAD-181088. [Epub ahead of print]
| Authors/Editors: | Alexopoulos P, Thierjung N, Economou P, Werle L, Buhl F, Kagerbauer S, Papanastasiou AD, Grimmer T, Gourzis P, Berthele A, Hemmer B. Kübler H, Martin J, Politis A, Perneczky R. |
|---|---|
| Publication Date: | 2019 |
Abstract
Cost- and time-effective markers of Alzheimer's disease (AD), reliable and feasible at the population level are urgently needed. Soluble amyloid-β protein precursor β (sAβPPβ) in plasma has attracted scientific attention as a potential AD biomarker candidate. Here we report that plasma sAβPPβ levels in patients with AD dementia and typical for AD cerebrospinal fluid (CSF) biomarker profiles (N = 33) are significantly lower (p < 0.01) than those of cognitively healthy elderly individuals without AD (N = 39), while CSF sAβPPβ levels did not differ between the studied groups. This provides further evidence for the potential of sAβPPβ in plasma as an AD biomarker candidate.
